Besponsa

Active Ingredient(s): Inotuzumab Ozogamicin
FDA Approved: * August 17, 2017
Pharm Company: * WYETH PHARMS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Besponsa Overview

Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.[1][2] It consists of the humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.[3] This drug was discovered by scientists collaborating at Celltech and Wyeth, and it was developed by Pfizer which had acquired Wyeth. Contents 1 Medical use 2 Adverse e...

Read more Besponsa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Inotuzumab_ozogamicin

Recent Besponsa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Besponsa: (1 result)

Sorted by National Drug Code

• 0008-0100 Besponsa .25 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc.

Other drugs which contain Inotuzumab Ozogamicin or a similar ingredient: (1 result)